Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients wi...

by Enrique Gomez-Gomez, Sara Moreno Sorribas, Jose Valero-Rosa, Ana Blanca, Juan Mesa, Joseba Salguero, Julia Carrasco-Valiente, Daniel López-Ruiz, Francisco José Anglada-Curado
Published 2021-07-01

Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer

by Enrique Gómez-Gómez, Juan M. Jiménez-Vacas, Sergio Pedraza-Arévalo, Fernando López-López, Vicente Herrero-Aguayo, Daniel Hormaechea-Agulla, José Valero-Rosa, Alejandro Ibáñez-Costa, Antonio J. León-González, Rafael Sánchez-Sánchez, Teresa González-Serrano, Maria J. Requena-Tapia, Justo P. Castaño, Julia Carrasco-Valiente, Manuel D. Gahete, Raúl M. Luque
Published 2019-09-01

The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness

by Daniel Hormaechea-Agulla, Manuel D. Gahete, Juan M. Jiménez-Vacas, Enrique Gómez-Gómez, Alejandro Ibáñez-Costa, Fernando L-López, Esther Rivero-Cortés, André Sarmento-Cabral, José Valero-Rosa, Julia Carrasco-Valiente, Rafael Sánchez-Sánchez, Rosa Ortega-Salas, María M. Moreno, Natia Tsomaia, Steve M. Swanson, Michael D. Culler, María J. Requena, Justo P. Castaño, Raúl M. Luque
Published 2017-08-01